Opens in a new windowwww.cannadorra.com

The product, which is being developed by GW Pharmaceuticals, is a mouth spray that contains cannabidiol (CBD), a non-psychoactive compound found in cannabis. The spray is being tested as a treatment for epilepsy.The NHS is testing a cannabis product for the first time. The product, which is being developed by GW Pharmaceuticals, is a mouth spray that contains cannabidiol (CBD), a non-psychoactive compound found in cannabis. The spray is being tested as a treatment for epilepsy.

Cannabidiol (CBD) mouth spray

The trial, which is being conducted at a number of hospitals across the UK, is investigating the effectiveness of the spray in reducing the frequency and severity of seizures in adults with epilepsy. The spray is being compared to a placebo, and participants will be randomly assigned to one of the two groups.

The trial is expected to last for two years, and the results are expected to be published in 2024. If the trial is successful, the spray could be made available on the NHS as a treatment for epilepsy.

Epilepsy is a neurological disorder that affects about one in 50 people in the UK. It is characterized by recurrent seizures, which are sudden bursts of electrical activity in the brain that can cause a variety of symptoms, including loss of consciousness, shaking, and muscle spasms.

Current treatments for epilepsy include medication, surgery, and diet therapy. However, some people with epilepsy do not respond to these treatments, and they continue to have seizures despite taking medication or having surgery.

The trial of the cannabis-based mouth spray is a promising development for people with epilepsy who do not respond to other treatments. CBD is a non-psychoactive compound that has been shown to have anti-seizure properties in animal studies. The trial is investigating whether CBD is effective in reducing seizures in people with epilepsy.

The results of the trial are eagerly awaited by people with epilepsy, their families, and healthcare professionals. If the trial is successful, the spray could provide a new treatment option for people with epilepsy who do not respond to other treatments.

Epilepsy is a neurological disorder that affects about one in 50 people in the UK. It is characterized by recurrent seizures, which are sudden bursts of electrical activity in the brain that can cause a variety of symptoms, including loss of consciousness, shaking, and muscle spasms¹.

Current treatments for epilepsy include medication, surgery, and diet therapy. However, some people with epilepsy do not respond to these treatments, and they continue to have seizures despite taking medication or having surgery¹.

The trial of the cannabis-based mouth spray is a promising development for people with epilepsy who do not respond to other treatments. CBD is a non-psychoactive compound that has been shown to have anti-seizure properties in animal studies. The trial is investigating whether CBD is effective in reducing seizures in people with epilepsy¹.

The results of the trial are eagerly awaited by people with epilepsy, their families, and healthcare professionals¹.

Learn more:

1. epilepsy.com2. bing.com3. jamanetwork.com4. mdpi.com5. investor.jazzpharma.com6. en.wikipedia.org